Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JNGHF)
| Market Cap | 45.28B -26.7% |
| Revenue (ttm) | 4.61B +3.9% |
| Net Income | 1.14B +5.1% |
| EPS | 0.17 +0.3% |
| Shares Out | n/a |
| PE Ratio | 39.81 |
| Forward PE | 31.08 |
| Dividend | 0.03 (0.48%) |
| Ex-Dividend Date | Apr 29, 2026 |
| Volume | n/a |
| Open | 6.10 |
| Previous Close | 6.10 |
| Day's Range | 6.10 - 6.10 |
| 52-Week Range | 6.10 - 8.87 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About JNGHF
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China. [Read more]
Financial Performance
In 2025, JNGHF's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.
Financial numbers in CNY Financial StatementsNews
China rushes to develop Moderna-style cancer vaccines amid market frenzy
A group of Hong Kong-listed biotechnology companies have seen their stock prices surge in the wake of Moderna’s breakthrough cancer vaccine trial, as the Chinese companies push forward with similar va...
China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs
Jiangsu Hengrui Pharmaceuticals , China's biggest drugmaker by market value, reported a 0.34% rise in first-half net profit on Wednesday, as its generics business remained under pressure from bulk-pro...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: H1 2026
Jiangsu Hengrui Pharmaceuticals Co.,Ltd has published its H1 2026 quarterly earnings report on August 18, 2026.
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
Leading Chinese drugmakers with global ambitions such as Jiangsu Hengrui Pharmaceuticals and CanSino Biologics are struggling to recruit internationally experienced staff needed to develop and commer...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: Q1 2026
Jiangsu Hengrui Pharmaceuticals Co.,Ltd has published its Q1 2026 quarterly earnings report on April 22, 2026.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Annual report: H2 2025
Jiangsu Hengrui Pharmaceuticals Co.,Ltd has published its H2 2025 annual report on March 25, 2026.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Earnings release: H2 2025
Jiangsu Hengrui Pharmaceuticals Co.,Ltd released its H2 2025 earnings on March 25, 2026, summarizing the period's financial results.
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: Q3 2025
Jiangsu Hengrui Pharmaceuticals Co.,Ltd has published its Q3 2025 quarterly earnings report on October 27, 2025.